New York, June 4, 2026, 13:04 (EDT)
- Clearmind Medicine stock rose 1.7% to $2.96 in midday action on the Nasdaq.
- The company put out word of a $1.5 million convertible-note deal this week. It also has a CMND-100 clinical-trial webinar scheduled for June 10.
- The company’s latest annual filing pointed to funding needs and raised substantial doubt about whether it can keep operating as a going concern.
Clearmind Medicine Inc. traded up midday Thursday on Nasdaq. Investors looked at a new financing filing and waited for an update on the company’s lead alcohol-use-disorder study. The micro-cap biotech’s cash levels stayed in focus.
The stock gained 1.7% to $2.96, moving between $2.80 and $3.00 so far, with volume at roughly 52,846 shares on the latest feed. The move isn’t big, but for a smaller name, even some light action will shift the price.
Funding is a short-term hurdle. In a June 1 filing, Clearmind said it would sell $1.5 million in convertible promissory notes to CLA investors for $1.35 million in cash. These notes count as debt but can be converted to equity down the line, which could mean dilution for current shareholders if holders choose to convert.
That’s important since Clearmind is still in the clinic stage, not yet making or selling any drugs. Its main program, CMND-100, is a pill using MEAI now in trials for alcohol use disorder, which involves harmful drinking that’s hard to control.
Clearmind’s next update is a June 10 webinar for CMND-100. The company said it will discuss information from its FDA-approved Phase I/IIa study, which is mainly looking at safety, tolerability and drug levels. CEO Dr. Adi Zuloff-Shani called the safety data “positive” and said there were “encouraging signals.” GlobeNewswire
Clearmind said last month the Johns Hopkins Medicine Institutional Review Board gave the green light for the next parts of the trial. The IRB, which reviews human studies for ethics, signed off. Zuloff-Shani called it “another important step forward” for CMND-100. GlobeNewswire
Clearmind has been working to expand its MEAI intellectual property. The company said May 29 it had filed a Japanese patent application for depression treatments using 5-Methoxy-2-aminoindan, or MEAI. Clearmind said its portfolio has 19 patent families and 31 granted patents.
Investors are still working through the latest structure move. Clearmind did a 1-for-10 reverse share split effective May 21 as it aims to get back in line with Nasdaq’s minimum bid-price rule. The reverse split pulls shares together to increase the quoted share price, but doesn’t change the company’s value.
Psychedelic-drug stocks pointed in different directions. Compass Pathways gained 4.3%. AtaiBeckley slipped 1.5%. Developers in the space often move on clinical, financing or regulatory news instead of revenue.
But it’s a shaky foundation. Clearmind’s latest annual report shows no product revenue, a net loss of $3.9 million for the fiscal year ended Oct. 31, 2025, and a total deficit of $27.9 million. The auditors flagged it with going-concern language, saying there’s substantial doubt Clearmind can keep going without new funding.
The risks are clear. More financing may dilute holders, trial timelines could slip, and if CMND-100 shows weak results, shares could drift away from the science and trade on cash runway instead. Right now, investors are looking to the June 10 update and the next filing.
